Amount Raised
$100 Million
Round Type
Series D
AlamedaBiotechnologyHealth CareTherapeuticsInvestors
Description
Acepodia, a clinical stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) and allogeneic gamma delta 2 T-cell platforms to address gaps in cancer care, today announced a $100 million Series D financing led by Digital Mobile Venture with participation from additional existing investors. The funds will be used to progress the company's pipeline of enhanced cell therapies for solid tumors and hematologic cancers, including ACE1831 and ACE2016. ACE1831 is an anti-CD20 armed allogeneic gamma delta 2 T-cell therapy currently being studied in a Phase 1 trial for patients with non-Hodgkin Lymphoma. ACE 2016 is an anti-EGFR armed allogeneic gamma delta 2 T-cell therapy targeting EGFR-expressing solid tumors.
Quick answer
Acepodia raised $100 Million in a Series D round, dated June 6, 2023. Investors: Digital Mobile Venture. Acepodia is based in Alameda, California, United States.
- How much did Acepodia raise?
- Acepodia raised $100 Million in a Series D round on June 6, 2023.
- Who invested in Acepodia?
- Digital Mobile Venture is named as investors in this round.
- What does Acepodia do?
- Acepodia is a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) platform technology to address gaps in cancer care.
- Where is Acepodia based and how big is it?
- Acepodia is based in Alameda, California, United States.
- Who are the decision-makers at Acepodia?
- Fundz holds 1 contact at Acepodia. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Acepodia that raised within 45 days of this round, from Fundz verified event records.
- KayoThera, Inc. raised an undisclosed amount (Series A) on July 19, 2023.
- SURGE Therapeutics raised $32M (Series B) on July 19, 2023.
- Renibus Therapeutics raised $47M (Funding Round) on July 18, 2023.
- Tenpoint Therapeutics raised $70M (Series A) on July 12, 2023.
- Smartlens raised $6.1M (Series A) on July 11, 2023.
- TolerogenixX raised $13M (Series A) on July 6, 2023.
Who to call at Acepodia, and when
A new round usually means Acepodia is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Acepodia raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Acepodia, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Acepodia. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Acepodia raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Acepodia raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.